Strong Q2 earnings beat on both revenue ($4.71B vs. $4.67B consensus) and EPS ($2.90 vs. $2.77 consensus), raised full-year EPS guidance above consensus estimates, completed $2B share buyback, and CEO noted 90%+ of business achieved mid-single-digit growth, driving 5.9% stock price increase.
The article highlights BDX's attractive valuation (P/E of 12 vs. 5-year average of 17), consistent 50+ year dividend growth history, recurring revenue model from essential medical supplies, active share buyback program, and resilience against industry-specific headwinds affecting pharma and care providers. These factors position it favorably for capital preservation and income generation.
Articles that tag BDX but are mainly about other companies.
Listed among key market leaders in multiplex assays, positioned to benefit from the market's projected growth driven by precision medicine and clinical panel expansion.
BD expanded Neopak XtraFlow glass syringe capacity sevenfold and collaborated with Ypsomed on device-platform co-development, demonstrating strong market positioning and investment in prefilled syringe technology.
Noted as a Dividend King healthcare company currently out of favor with investors, making it attractively priced with dividend yield above its five-year average, suggesting good value for long-term holders.
Identified as a key market participant in the expanding apheresis market with growing demand for blood components and plasma-derived products.
Major player with relevant products (BD Max System, BD Vacutainer Blood Collection Tubes) positioned to benefit from growing blood transfusion diagnostics market.
Benefits from GLP-1 boom as a leading supplier of prefillable syringes; investing $110 million in capacity expansion; generates 90%+ recurring revenue; Dividend King with 54 consecutive years of increases.
Listed as a leading market player with significant commercial concentration in North America. BD Diagnostics' automated blood culture systems are driving market adoption and growth.
Leading market player with strong positioning in the growing enteric disease testing market driven by increasing demand for advanced diagnostic infrastructure and laboratory automation.
Dividend King with 54 consecutive yearly increases, strong patent portfolio with $1 billion annual R&D spending, dividend at one-third of earnings estimates providing safety margin.
Major player in the wound irrigation systems market with exposure to growing surgical and chronic wound care segments.
53 consecutive years of dividend growth, defensive business model with recurring hospital/clinic purchases, credible growth story in diagnostics and medication management, dividend yield above S&P 500 average at 2.8%, and recession-resistant revenue profile with low existential business risk.
Leading market player with recent 2026 developments advancing drug-device combination strategies for microneedle-enabled injectable alternatives in chronic disease applications.
Referenced as another healthcare Dividend King alternative, but similarly noted as less preferable to J&J due to specialization in medical devices only, lacking the diversification benefits of J&J's combined portfolio.
Listed as a key player in the growing nebulizer market with expanding opportunities in respiratory care solutions and home healthcare adoption.
Key market player with FDA clearance for BD Onclarity HPV Self-Collection Kit in April 2026, expanding at-home screening access
Key market player in HPV testing and diagnostic instruments, positioned to capture market share in growing screening market
Key player in the market positioned to benefit from growing adoption of home diagnostic testing and digital health integration trends.
Trading at significant valuation discount (13x forward P/E) relative to peers despite strong fundamentals including market-leading infusion pump position, record operating margins (25%), high recurring revenue (90%+), and secular tailwind from GLP-1 biologics delivery platform targeting $1B revenue by 2030. Transition year noise masks improving operational trajectory with 80bps annual margin expansion and $4B capital deployment. Upside potential of 26-58% to normalized 17-20x multiples with limited downside risk.
Identified as a key player in the China diabetes devices market, positioned to benefit from growing demand for insulin delivery and glucose monitoring devices.
Trading at 12x forward earnings (discount to peers), recent spinoff provides $4B cash for buybacks/acquisitions, analysts forecast earnings rebound in 2027, 54+ year dividend growth track record, 2.7% forward dividend yield with 5.5% average annual growth
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
